project id: TCGA-PRAD; case submitter id: TCGA-EJ-A7NK; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.78; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.2; rna integrity number: 7.6; age at index: 58; days to birth: -21530; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1954; age at diagnosis: 21530; ajcc clinical m: M0; ajcc clinical t: T3a; ajcc pathologic n: N0; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 476.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 254; initial weight: 140.0; sample id: d97ce5bb-672c-4ed7-a81a-c22cd32a3631; sample submitter id: TCGA-EJ-A7NK-01A; portion id: b37b773b-e890-44d7-8f51-3bd48962653e; portion submitter id: TCGA-EJ-A7NK-01A-12; slide id: 448f57d7-002a-4f2d-8e56-fa3e13b4446d; slide submitter id: TCGA-EJ-A7NK-01A-01-TS1; percent lymphocyte infiltration: 40.0; percent monocyte infiltration: 20.0; percent necrosis: 0.0; percent neutrophil infiltration: 20.0; percent normal cells: 0.0; percent stromal cells: 30.0; percent tumor cells: 70.0; percent tumor nuclei: 70.0; section location: TOP;